علاج خلل الحركة المتأخر المزعج (متوسط الشدة على الأقل) في المرضى ذوي مؤشر مضادات الذهان المعتمد

References

DOI: 10.1016/j.jns.2018.02.010

In patients with troublesome TS, suppressive agents should be considered.

Suppressive therapy should be considered when disabilities are at least moderate and interfere with ADLs and QoL, with new VMAT2 inhibitors or TBZ (if both Deut-TBZ and valbenazine are not available) as the first-line treatment, with clonazepam and Ginkgo biloba as second-line, and combined with amantadine if symptoms are still troublesome.

In those who cannot tolerate or fail Deut-TBZ or valbenazine, clonazepam or gingko biloba can be considered as alternatives.

Clonazepam should be initiated at 0.5 mg and titrated slowly, not exceeding 4.5 mg daily.

Ginkgo biloba extract (EGb-761) dosage is recommended at 240 mg once daily.